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Accumulating evidence suggests that codeletion
of the tumor suppressor genes Pten and p53 plays
a crucial role in the development of castration-resis-
tant prostate cancer in vivo. However, the molecular
mechanism underlying Pten-/p53-deficiency-driven
prostate tumorigenesis remains incompletely un-
derstood. Building upon insights gained from our
studies with Pten-/p53-deficient mouse embryonic
fibroblasts (MEFs), we report here that hexokinase
2 (HK2) is selectively upregulated by the combined
loss of Pten and p53 in prostate cancer cells. Mech-
anistically, Pten deletion increases HK2mRNA trans-
lation through the activation of the AKT-mTORC1-
4EBP1 axis, and p53 loss enhances HK2 mRNA
stability through the inhibition of miR143 biogen-
esis. Genetic studies demonstrate that HK2-medi-
ated aerobic glycolysis, known as the Warburg
effect, is required forPten-/p53-deficiency-driven tu-
mor growth in xenograft mouse models of prostate
cancer. Our findings suggest that HK2 might be a
therapeutic target for prostate cancer patients car-
rying Pten and p53 mutations.
INTRODUCTION
Prostate cancer is the second leading cause of cancer-related
deaths in men after lung cancer in the United States. Prostate
cancer arises mainly from prostatic intraepithelial neoplasia
(PIN), a precursor lesion that ultimately progresses to adeno-
carcinoma and metastatic diseases (DeMarzo et al., 2003).
The initiation, progression, and metastasis of prostate cancer
involve alterations of multiple tumor suppressor genes, such
as Pten (phosphatase and tensin homolog deleted on chromo-Cell Resome 10) and p53 (Shen and Abate-Shen, 2010). Loss of one
allele of PTEN occurs frequently in primary prostate cancers,
and homozygous deletion of PTEN is found in 70% of advanced
prostate cancers (Cairns et al., 1997; Gray et al., 1995; Suzuki
et al., 1998; Whang et al., 1998). Similarly, p53 is often found
completely lost or mutated in advanced human prostate
cancers (Navone et al., 1999). Recent advances in whole-
genome/exome sequencing analyses reveal that PTEN and
p53 are often codeleted or comutated in lethal castration-resis-
tant prostate cancers (CRPC) (Grasso et al., 2012). Systems
bioinformatics analyses estimate that prostate cancers with
combined loss of PTEN and p53make up 11% of highly aggres-
sive prostate cancers and bestow the worst survival outcome
for patients (Markert et al., 2011). Importantly, tracking the
clonal origin of lethal prostate cancer through patient samples
collected during tumor progression and at the time of death
identified that the lethal metastatic clone arose from primary
prostate cancer cells carrying PTEN deletion and mutant p53
(Haffner et al., 2013). Mouse genetic studies suggest that Pten
deletion in prostate epithelial cells primarily initiates PIN,
whereas p53 loss in prostate epithelial cells is not sufficient to
cause any distinguishable morphological phenotypes in vivo.
However, double deletion of Pten and p53 in prostate epithelial
cells leads to invasive prostate cancer with salient features of
human CRPC (Lunardi et al., 2013; Y.D. et al., unpublished
data). These clinical and experimental findings implicate that
loss of Pten and p53 in prostate epithelial cells plays a causal
role in CRPC. However, the molecular mechanism underlying
Pten- and p53-deficiency-driven prostate tumorigenesis re-
mains incompletely understood.
PTEN, by dephosphorylating the 30 position of phosphatidyli-
nositol-3,4,5-trisphosphate (PIP3) to phosphatidylinositol 4,5-bi-
sphosphate (PIP2), antagonizes the phosphatidylinositol-3-OH
kinase (PI3K)-AKT signaling pathway that stimulates cell meta-
bolism, growth, and survival (Song et al., 2012). Downstream
of the PI3K-AKT kinase pathway, mammalian target of rapamy-
cin (mTOR) assembles with regulatory-associated protein ofports 8, 1461–1474, September 11, 2014 ª2014 The Authors 1461
mTOR (Raptor) to form mTOR complex 1 (mTORC1) or with Ric-
tor to form mTOR complex 2 (mTORC2) (Guertin and Sabatini,
2007). Both complexes exert their actions by phosphorylating
their unique substrates. mTORC1 phosphorylates p70 ribosomal
protein S6 kinase (S6K) and 4E-binding protein 1 (4E-BP1;
also known as eIF4E-BP1) to increase protein synthesis, which
facilitates cell survival, proliferation, and growth (Laplante and
Sabatini, 2012). mTORC2 facilitates the activation of AKT by
phosphorylating AKT on serine 473 (Jacinto et al., 2006; Sarbas-
sov et al., 2005). Studies of genetically engineered prostate
cancer mouse models coupled with whole-genome/exome
sequencing analyses of human prostate cancers suggest that
aberrant activation of the PI3K-AKT-mTOR signaling pathway
plays a causal role in Pten-deficiency driven prostate tumorigen-
esis (Barbieri et al., 2012; Chen et al., 2006; Grasso et al., 2012).
Interestingly, it has been shown recently that loss of Pten in-
duces ER UDPase ectonucleoside triphosphate diphosphohy-
drolase 5 (ENTPD5), and activation of the AKT/mTOR pathway
leads to induction of pyruvate kinase isoenzyme type M2
(PKM2), which contribute to aerobic glycolysis, also known as
the Warburg effect, and tumor growth in a xenograft model of
prostate cancer (Fang et al., 2010; Sun et al., 2011). These re-
sults suggest that dysregulation of the PTEN-PI3K-AKT-mTOR
pathway in prostate cancer cells could cause theWarburg effect,
which in turn facilitates prostate cancer development.
The well-established tumor suppressor protein p53 plays
important roles not only in mediating cell-cycle arrest, senes-
cence, autophagy, and apoptosis but also in regulating cell
metabolism. p53 inhibits aerobic glycolysis by inducing expres-
sion of the TP53-induced glycolysis and apoptosis regulator (TI-
GAR) (Bensaad et al., 2006) and Parkin (Zhang et al., 2011) or by
decreasing the expression of glycolytic enzyme phosphoglyc-
erate mutase 1 (PGAM1) (Kondoh et al., 2005). p53 shifts cellular
metabolism and energetics from the glycolytic pathway toward
the respiratory pathway through induction of synthesis of cyto-
chrome c oxidase 2 (SCO2) (Matoba et al., 2006). p53 also en-
hances mitochondrial respiration by inducing glutaminase 2
(GLS2) (Hu et al., 2010; Suzuki et al., 2010). In addition, p53
can directly interact with glucose-6-phosphate dehydrogenase
(G6PD) to suppress the pentose phosphate pathway, which
branches out from glycolysis by utilizing glycolytic intermediates
to produce metabolites vital for biosynthesis (Jiang et al., 2011).
Therefore, the loss ormutation of p53might promote and sustain
tumor growth by enhancing the Warburg effect and anabolic
(biosynthesis) pathways.
Hexokinases (HKs) catalyze the essentially irreversible first
step of glycolytic pathway by phosphorylating glucose to
glucose-6-phosphate (G-6-P). There are four isoforms encoded
by the separate genes: HK1, HK2, HK3, and HK4 (also known as
glucokinase). HK1 is ubiquitously expressed in almost all
mammalian tissues, and HK2 is normally expressed in insulin-
sensitive tissues such as adipose, skeletal, and cardiacmuscles.
HK3 is usually expressed at low levels and HK4 expression is
restricted to the pancreas and liver (Wilson, 2003). A high level
of HK2 expression has been observed in cancer cells and is
associated with poor overall survival in cancer patients (Mathu-
pala et al., 2001; Wolf et al., 2011). Importantly, genetic studies
utilizing mouse models demonstrated that HK2 plays an essen-1462 Cell Reports 8, 1461–1474, September 11, 2014 ª2014 The Autial role in Kras-driven lung cancer and ErbB2-driven breast can-
cer in vivo (Patra et al., 2013). However, whether and how loss of
Pten and p53 in prostate epithelial cells induces the HK2-medi-
ated Warburg effect to contribute to prostate tumorigenesis has
not yet been explored.
Through integrated analyses of Pten-/p53-deficient mouse
embryonic fibroblasts (MEFs), prostate cancer cell lines, xeno-
grafts, and genetically engineered mouse models as well as
clinic prostate cancer samples, we show herein that Pten/p53
deficiency selectively enhances expression of HK2, but not
HK1, through posttranscriptional and translational regulation.
More importantly, genetic studies suggest that the HK2-medi-
ated Warburg effect is required for Pten- and p53-deficiency-
driven prostate tumor growth in vivo.
RESULTS
HK2-Mediated Warburg Effect Is Required for Cell
Transformation and Tumorigenesis
To study whether and how loss of Pten and p53 causes tumori-
genesis, we generated primary MEFs carrying either floxed Pten
alleles (PtenF/Fp53+/+), floxed p53 alleles (Pten+/+p53F/F), or both
(PtenF/Fp53F/F) (Figures S1A and S1B). Subsequent Cre-loxP-
mediated recombination gave rise to cells deficient in Pten
(PtenD/Dp53+/+), p53 (Pten+/+p53D/D), or both (PtenD/Dp53D/D),
as evident by PCR genotyping andwestern blot analysis (Figures
S1C and S1D). We confirmed that loss of Pten activated
p53-mediated senescence as reported previously (Chen et al.,
2005), whereas loss of p53 caused immortalization of MEFs as
the cells bypassed senescence (Figures S2A–S2C). While single
deletion of neither Pten nor p53 in MEFs led to cellular transfor-
mation, double deletions of Pten and p53 transformedMEFs and
endowed them with the ability to form tumor in nonobese dia-
betic/severe combined immunodeficiency (NOD/SCID) IL2RG
(NSG) mice (Figures S2D–S2G). Our findings suggest that the
combined inactivation of Pten and p53 in MEFs is sufficient
and required to cause cell transformation and tumorigenesis
in vivo.
As the culture media of PtenD/Dp53D/D MEFs turned yellow
much faster than that of Pten+/+p53D/D MEFs, we hypothesized
that this phenotype might be due to lactate acidosis. Indeed,
glucose consumption and lactate production were significantly
increased in PtenD/D p53D/D MEFs compared with Pten+/+
p53D/D MEFs (Figures 1A and 1B). Since these metabolic
changes resembled aerobic glycolysis, we screened for the
molecular candidates contributing to the alterations of glucose
and lactate metabolism by immunoblotting. HK2, but not HK1,
was identified to be markedly elevated in Pten-/p53-deficient
MEFs (Figure 1C).
We then knocked down HK2 expression in Pten-/p53-defi-
cient MEFs to investigate whether it was required for induction
of the Warburg effect and tumor formation in vivo. Lentivirus-
mediated small hairpin RNA (shRNA) targeting mouse HK2
caused a significant reduction of endogenous HK2, but not
HK1 (Figure 1D). Depletion of HK2 in Pten-/p53-deficient
MEFs significantly reduced glucose consumption (Figure 1E)
and lactate production (Figure 1F), attenuated anchorage-inde-
pendent cell growth on soft agar (Figures 1G and 1H), andthors
Figure 1. The HK2-Mediated Warburg Effect
Is Required for Tumorigenesis in Pten-/p53-
Deficient MEFs
(A and B) Glucose consumption (A) and lactate
production (B) in Pten+/+p53D/D and PtenD/Dp53D/D
MEFs.
(C) Lysates from Pten+/+p53D/D and PtenD/Dp53D/D
MEFs were immunoblotted by the indicated anti-
bodies.
(D) Lysates from PtenD/Dp53D/D MEFs carrying
shRNA for mouse HK2 or expressing human HK2
were determined by western blotting.
(E and F) Glucose consumption (E) and lactate
production (F) in HK2-depleted or human HK2-
rescued PtenD/Dp53D/D MEFs.
(G) Representative images of HK2-deficient or
human HK2-rescued MEFs growing in soft agar.
(H) Quantification of macroscopic colonies in (G)
from three independent experiments.
(I) Weight of tumors developed from NOD/SCID
IL2RG mice carrying HK2-deficient or human HK2-
rescued PtenD/Dp53D/D MEFs. For western blots,
tubulin was used as a loading control.
All data in the graph bars are means ± SEM.
*p% 0.01. ns, not statistically significant. Scale bar,
100 mm. See also Figures S1 and S2.impaired tumor growth in a xenograft model (Figure 1I). Note
the HK2 depletion-caused phenotypes were observed in the
presence of a physiological level of HK1. However, exogenous
expression of the human HK2, which is resistant to silencing
by the shRNA targeting mouse HK2, rescued the phenotypes
observed in mouse HK2-depleted MEFs (Figures 1E–1I). These
results support that the HK2-mediated Warburg effect is
required for Pten-/p53-deficiency-induced MEF transformation
and tumorigenesis in vivo.
Loss of Pten and p53 in Prostate Epithelial Cells
Robustly Enhances HK2 Protein Expression
To determine whether the increased HK2 expression in Pten-/
p53-deficient MEFs could be observed in human prostate can-
cer cells carrying similar genetic aberrations, we screened
several human prostate cancer cell lines for HK2 protein expres-
sion by immunoblotting. As shown in Figure 2A, HK2 was signif-
icantly elevated in PC3 cells (Pten/p53 deficiency) comparedCell Reports 8, 1461–1474, Sewith LNCaP cells (Pten deficiency with
wild-type p53), but no signal or very
weak HK2 expression was detected in
DU145 cells (wild-type Pten with mutant
p53) or the nontumorigenic human pros-
tate epithelium RWPE-1 cells (wild-type
Pten with functionally inactivated p53).
To pathogenetically simulate the Pten
change as in PC3 cells, we established
DU145 and RWPE-1 cells stably express-
ing two different sets of shRNA for human
Pten. Depletion of Pten in DU145 and
RWPE-1 cells induced HK2 expression
(Figures 2B and 2E), accompanied by in-creased glucose consumption (Figures 2C and S3A) and lactate
production (Figures 2D and S3B) in the respective cell line.
Importantly, reduction of Pten promoted the transformation of
RWPE-1 cells, as evident by their acquired ability to grow in
soft agar (Figures S3C and S3D). However, there was no signif-
icant difference of HK1 protein expression in these cells upon
Pten depletion (Figures 2B and 2E). These data suggest that
inactivation of Pten in human prostate epithelial cells with mutant
or inactivated p53 is sufficient for the enhanced expression of
HK2 without affecting HK1 and that HK2 in turn facilitates the
Warburg effect and drives cell transformation.
To determine whether HK2 expression in prostate epithelial
cells is increased upon loss of Pten and p53 in vivo, we collected
prostate tissue from genetically engineered mouse models with
deletion of either Pten or p53 and deletion of both specifically in
prostate epithelial cells by crossbreeding mice harboring Proba-
sin-Cre4 (Pb-Cre4) (Wu et al., 2001), floxed Pten alleles (Zheng
et al., 2008), and/or floxed p53 alleles (Jonkers et al., 2001).ptember 11, 2014 ª2014 The Authors 1463
Figure 2. HK2 Protein Expression Is
Elevated in Pten-/p53-Deficient Prostate
Cancer Cells
(A) Lysates from human prostate cancer cell lines
and untransformed human prostate epithelial cells
were immunoblotted by the indicated antibodies.
(B) Protein levels of Pten, HK2, and HK1 were
detected by western blotting in DU145 cells ex-
pressing shRNAs for Pten.
(C and D) Glucose consumption (C) and lactate
production (D) in Pten-depleted DU145 cells.
(E) Protein levels of Pten, HK2, and HK1 were
determined by western blotting in RWPE-1 cells
expressing shRNAs for Pten.
(F) Representative images of hematoxylin/eosin
staining of prostate from the indicated genotypes.
(G) Extracts from prostate of 20-week-old mice of
the identified genotypes were immunoblotted by
the indicated antibodies.
(H) Representative IHC images of HK2-stained
prostate epithelium with the indicated genotype
are shown.
(I) Quantification of HK2 IHC staining was per-
formed with Image-Pro plus (v 6.3) and is shown in
bar graphs. For western blots, tubulin was used as
a loading control.
All data in the graph bars represent means ± SEM.
*p % 0.01. Scale bar, 100 mm. See also Figures
S3–S5.Genetic deletions were confirmed by PCR genotyping (Fig-
ure S4A), immunohistochemistry (IHC) staining (Figure S4B),
and western blot (Figure 2G). By 20 weeks of age, the prostate
tumor in Pten-/p53-deficient mice encompassed the entire
genitourinary tract. In contrast, Pten-deficient mice retained
recognizable but enlarged anterior prostate (AP), ventral pros-
tate (VP), and dorsolateral prostate (DLP) lobes (Figure S5A).
The average tumor weight in Pten-/p53-deficient mice was 20
times that of Pten-deficient mice (Figure S5B). Histopathology
of Pten-/p53-deficient prostate tumors indicated invasive carci-
nomas, whereas Pten-deficient prostate had mainly high-grade
prostatic intraepithelial neoplasia (HG-PIN). However, prostate
histology of age-matched p53-deficient mice did not differ
from those of the wild-type mice (Figure 2F).
As expected (Chen et al., 2005), Pten deletion in prostate
epithelial cells resulted in AKT phosphorylation and p53 induc-1464 Cell Reports 8, 1461–1474, September 11, 2014 ª2014 The Authorstion (Figure 2G, lane 3 versus 1). Whereas
HK2 protein expression was below the
limit of detection in wild-type or p53-defi-
cient prostate (Figure 2G, lanes 1 and 4), it
was detectable in Pten-deficient prostate
(Figure 2G, lane 3) and was significantly
enhanced in Pten-/p53-deficient prostate
analyzed by western blot (Figure 2G,
lane 2) and confirmed by IHC staining (Fig-
ures 2H and 2I). However, no significant
changes of HK1 protein expression were
observed in the prostate with various ge-
notypes (Figure 2G). These findings sup-
port that codeletions of Pten and p53 inprostate epithelial cells selectively enhance HK2 expression in
mouse models.
PTEN Deletion Increases HK2 mRNA Translation
through AKT-mTORC1-4EBP1 Signaling
To understand the molecular mechanism underlying how loss
of Pten and/or p53 upregulates HK2, we examined HK2 mRNA
level in MEFs with defined genetic changes by real-time RT-
PCR. HK2 mRNA expression was not induced upon loss of
Pten (Figure 3A, column 2 versus 1), whereas it was dramatically
increased in MEFs with loss of p53 (Figure 3A, column 3 versus
1). No further enhanced HK2 mRNA was observed in Pten-/p53-
deficient MEFs (Figure 3A, column 4 versus 3). To exclude cell-
type-dependent regulatory mechanisms, we analyzed HK2
mRNA expression in prostate tissue/tumors derived from Pten
and/or p53 conditional knockout mouse models and observed
Figure 3. PTEN-AKT-mTORC1 Signaling Regulates HK2 Protein Expression
(A–D) HK2 mRNA (A and C) and HK1 mRNA (B and D) expression in MEFs and in prostate with the indicated genotypes was examined by real-time RT-PCR.
(E–P) Effects of knocking down AKT or Raptor on HK2 expression. HK2 protein expression was determined by western blot in PtenD/Dp53D/DMEFs with depletion
of AKT (E) or Raptor (F), inmousePtenD/Dp53D/D prostate cancer cells with depletion of AKT (I) or raptor (J), and in humanPten-/p53-deficient prostate cancer PC3
cells with depletion of AKT (M) or Raptor (N). HK2 mRNA expression was detected by real-time RT-PCR in AKT- or Raptor-depleted Pten-/p53-deficient MEFs
(G and H), in AKT- or Raptor-depleted Pten-/p53-deficient mouse prostate cancer cells (K and L), and in AKT- or Raptor-depleted Pten-/p53-deficient human
prostate cancer cells (O and P).
For western blots, tubulin was used as a loading control. All data are means ± SEM. *p% 0.01. ns, not statistically significant. See also Figure S6.
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Figure 4. Pten Deficiency Translationally
Upregulates HK2 through Phosphorylation
of 4E-BP1
(A) Schematic presentation of total, mono-
ribosomal, and polysomal mRNA distribution after
different centrifugation.
(B–D) Real-time RT-PCR analysis of total HK2
mRNA levels and the HK2 mRNA loaded on
polysomes (left panel) in MEFs carrying p53D/D or
PtenD/Dp53D/D (B) or in Pten-/p53-deficient mouse
prostate cancer UMN-4240P cells expressing
shRNA for Raptor (C) or in Pten-/p53-deficient
human prostate cancer PC3 cells expressing
shRNA for AKT (D). The respective right panel
shows the ratio between the level of HK2 mRNA
loaded on the polysome and the total HK2 mRNA.
Note that each value was normalized to total
b-actin expression and b-actin loaded on the
polysome.
(E and F) Phosphorylation of 4EBP1 regulates HK2
expression. Immunoblots of lysates from PC3
cells were treated with NVP-BEZ235 or rapamycin
at the indicated doses for 36 hr (E), and HK2
expression was determined by western blotting
from PC3 cells expressing tetracycline-inducible
dominant-negative mutant 4EBP1M after 48 hr
doxycycline (1 mg/ml) treatment (F).
(G) Schematic model addressing HK2 upregula-
tion upon Pten deletion.
For western blots, tubulin was used as a loading
control. All data are means ± SEM. *p% 0.01. ns,
not statistically significant. See also Figure S6.identical results as in MEFs (Figure 3C). It is particularly note-
worthy that p53 deletion increased HK2 mRNA (Figures 3A
and 3C) but failed to increase the HK2 protein level (Figure 2G),
whereas Pten deletion did not increase HK2 mRNA (Figures 3A
and 3C) yet increased HK2 protein, although not to the signifi-
cant extent that the double deletion of Pten and p53 achieved
(Figure 2G). We also examined HK2 mRNA levels in Pten-
depleted-DU145 or -RWPE-1 cells and found no difference
with their respective parental cells (Figures S6A and S6B). Inter-
estingly, HK2 mRNA expression in DU145 cells is significantly
elevated compared to LNCaP cells (Figure S6C). However,
expression of protein HK2 in DU145 cells is barely detected (Fig-
ure 2A). No significant difference of HK1 mRNA was observed
in these models carrying various genotypes (Figures 3B, 3D,1466 Cell Reports 8, 1461–1474, September 11, 2014 ª2014 The Authorsand S6D). These data together suggest
the possibility that p53 selectively regu-
lates HK2 at the mRNA level, whereas
Pten predominantly regulates HK2 at the
protein level.
Given that previous studies supported
that AKT-mTORC1 pathway plays an
important role in Pten-deficiency-
driven prostate tumorigenesis, we uti-
lized both genetic and pharmacological
approaches to determine the role of
AKT-mTORC1-4EBP1-mediated 50 cap-
dependent translation signaling in upre-gulating HK2 protein expression upon Pten deletion. Depletion
of AKT or Raptor (an essential component of mTORC1 complex)
by shRNAs in Pten/p53 double-deficient MEFs reduced HK2
protein expression but had no effect on HK1 protein expression
(Figures 3E and 3F). Knockdown of AKT or Raptor in prostate
cancer cell line UMN-4240P, derived from a prostate tumor in
Pten-/p53-deficient mice (Figures 3I and 3J) or in human pros-
tate cancer cell line PC3 (Figures 3M and 3N), resulted in a sig-
nificant reduction of protein expression of HK2 but little, if any,
effect on HK1 expression (Figures 3I, 3J, 3M, and 3N). Further-
more, pharmacological inhibition of the AKT-mTORC1-mediated
translation pathway in PC3 cells with the PI3K-mTOR dual inhib-
itor NVP-BEZ235 remarkably reduced protein expression of
HK2, but not HK1 (Figure 4E). In contrast to a marked reduction
of HK2 protein expression, there was no significant decrease of
HK2 mRNA in the AKT- or Raptor-depleted multiple cell lines or
BEZ235-treated PC3 cells (Figures 3G, 3H, 3K, 3L, 3O, 3P, and
S6E), suggesting AKT-mTORC1 signaling primarily regulates
HK2 expression at the translational level. In support of this pos-
sibility, loss of Pten increased the amount of HK2 mRNA loaded
on the polysome (Figures 4A and 4B), whereas genetic inhibition
of AKT-mTORC1 signaling significantly decreased polysome-
associated HK2 mRNA (Figures 4C and 4D), while the amount
of total HK2 mRNA remained unaffected (Figures 4B–4D).
The allosteric mTOR inhibitor rapamycin had minimal effects
on HK2 protein levels compared with BEZ235 (Figure 4E).
BEZ235 significantly inhibited activation of two primary down-
stream effectors in the AKT-mTORC1 pathway: 4EBP1 and
70S6K. However, rapamycin blocked only 70S6K phosphoryla-
tion in these cells (Figure 4E), suggesting that phosphorylation
and subsequent dissociation of 4EBP1 from the cap-binding
translation initiation factor eIF4E might play an important role in
regulating HK2 expression. To this end, we introduced tetracy-
cline-inducible nonphosphorylatable 4EBP1 expression system
(designed as dominant-negative mutant 4EBP1M) (Hsieh et al.,
2010) into PC3 cells to enhance binding capacity with eIF4E to
inhibit cap-dependent translation and observed that induction
of 4EBP1M expression significantly reduced HK2 protein expres-
sion (Figure 4F) without affecting HK2 mRNA (Figure S6F).
Collectively, our genetic and pharmacological studies support
that Pten deficiency leads to AKT-mTORC1-mediated phos-
phorylation of 4EBP1, which then dissociates from eIF4E to acti-
vate cap-dependent translation of HK2 mRNA (Figure 4G). In
addition, the inability of rapamycin to suppress 4EBP1-HK2
signaling might explain its lack of therapeutic benefits for pros-
tate cancer in experimental and clinical studies.
Loss of p53 Enhances HK2 mRNA through Inhibition of
miR143 Biogenesis
In contrast to an early study that wild-type p53 increased HK2
mRNA at the transcription level through p53-responsive ele-
ments (Mathupala et al., 1997), we found that loss of p53 signif-
icantly upregulated HK2 mRNA in MEFs (Figure 3A) and in pros-
tate epithelial cells (Figure 3C). Conversely, transient exogenous
expression of wild-type p53 in PC3 cells significantly reduced
HK2 protein expression (Figure 5A) and HK2 mRNA expression
(Figure 5B). Induced expression of endogenous p53 in LNCaP
cells with genotoxic drug Adriamycin (Figure 5D, lane 2 versus
1), but not in the LNCaP cells in which p53 was silenced by
shRNAs (Figure 5D, lane 4 versus 3 and lane 6 versus 5), de-
creased HK2 protein expression (Figure 5D) and HK2 mRNA
expression (Figure 5E). Interestingly, no significant induction of
HK2 was observed in LNCaP cells with shRNAs to deplete
endogenous p53 (Figure 5D, lanes 3 and 5 versus 1), possibly
due to ‘‘undetectable’’ endogenous p53 expression in LNCaP
cells and/or other unidentified genetic changes that might
contribute to HK2 mRNA regulation. However, these results
support that stress-induced wild-type p53 primarily suppresses
HK2 mRNA. To support the possibility that the inhibition of HK2
mRNA depended on endogenous p53, we compared p53 wild-
type HCT116 and isogenic p53 knockout HCT116 human colon
cancer cell lines upon Adriamycin challenge and found thatCell Rereduction of HK2 at mRNA level was observed in p53 wild-type
cells, but not in p53 knockout cells (Figures 5G and 5H).
Given that wild-type p53 facilitates the processing of miR143
(Suzuki et al., 2009) and that miR143 destabilizes HK2 mRNA
stability in several types of cancer cells (Fang et al., 2012; Gre-
gersen et al., 2012; Jiang et al., 2012; Peschiaroli et al., 2013),
we hypothesized that p53 might attenuate HK2 mRNA expres-
sion through upregulation of miR-143. Indeed, overexpression
of p53 in PC3 cells or induction of endogenous p53 in LNCaP
and HCT116 cells dramatically increased miR143 (Figures 5C,
5F, and 5I), correlating with a significant reduction of HK2
mRNA (Figures 5B, 5E, and 5H). To determine causality of sup-
pression of HK2 mRNA through miR143 in prostate cancer cells,
we overexpressed miR143 (Figure 5J, lane 2 versus 1) or admin-
istrated miR143 mimic in PC3 cells (Figure 5J, lane 3 versus 1)
and observed much-reduced HK2 protein expression (Figure 5J)
and concomitant reduction of HK2 mRNA (Figure 5K). These
results together suggest that loss of p53 inhibits miR143 biogen-
esis and relieves miR143-mediated suppression of HK2 mRNA
stability, thereby increasing HK2 mRNA (Figure 5L).
HK2 Is Required for Pten/p53 Deficiency-Driven
Prostate Tumor Growth in Xenograft Models
To investigate whether the upregulated HK2 expression in Pten-/
p53-deficient prostate cancer cells is required for the Warburg
effect and tumor growth, we knocked down HK2 through stably
expressing lentivirus-mediated shRNA in the established mouse
Pten-/p53-deficient prostate cancer cell line (UMN-4240P) (Fig-
ure 6A). Efficient knockdown of HK2 in cancer cells led to signif-
icant reduction of glucose consumption and lactate production
(Figures 6B and 6C) andmarkedly reduced cell proliferation (Fig-
ure 6D). More importantly, depletion of HK2 inhibited anchorage-
independent cancer cell growth (Figure 6E) and dramatically
attenuated the in vivo growth of these xenografted prostate can-
cer cells in NSG mice (Figure 6F).
To study the essential role of elevated HK2 in human Pten-/
p53-deficient prostate cancer cells, we generated two stable
cell lines in PC3 cells with varying degrees of reduction of HK2
expression: shHK2-02, which robustly decreased total HK2 pro-
tein, and shHK2-01, which reduced HK2 by a lesser degree (Fig-
ure 6I). Depletion of HK2 in these two PC3 cell lines resulted
in significantly reduced glucose consumption and lactate pro-
duction (Figures 6J and 6K), attenuated their colony growth
(Figure 6L), and inhibited anchorage-independent cell growth
examined by soft-agar assay (Figures 6M and 6N). Furthermore,
the growth of xenografted PC3 cells stably expressing shHK2-01
or shHK2-02 in NSG mice was significantly suppressed com-
pared to PC3 cells with a scramble shRNA (Figure 6O). When
necropsied at 4 weeks after subcutaneous inoculation, tumors
that derived from scrambled shRNA-expressing cells grew to
an average weight of 155 mg, whereas tumors that derived
from shHK2-01- and shHK2-02-expressing cells grew to an
average weight of 55 mg and 20 mg, respectively (Figure 6O).
Importantly, the magnitude of reduction in tumor weight as well
as in in vitro growth indices reflected the efficiency of the HK2
knockdown in PC3 cells.
We then examined the cellular processes underlying the sup-
pression of tumor growth in xenograft mouse models carryingports 8, 1461–1474, September 11, 2014 ª2014 The Authors 1467
Figure 5. p53 Deletion Upregulates HK2 mRNA through Inhibition of miR143 Biogenesis
(A–C) p53 regulates miR-143 and HK2 in PC3 cells. HK2 protein (A), HK2 mRNA levels (B) and miR-143 (C) were examined by western blotting or real-time
RT-PCR in PC3 cells expressing wild-type p53.
(D–F) Effects of shRNA knockdown of p53 on HK2 and miR143 expression in Adriamycin-treated LNCaP cells. HK2 protein levels (D) were detected by western
blot, and HK2 mRNA (E) and miR-143 (F) were measured by real-time RT-PCR and shown as means ± SEM (n = 3).
(G–I) Effects of p53 knockout onHK2 andmiR143 expression in Adriamycin-treated HCT116 cells. HK2 protein levels were examined bywestern blot (G), and HK2
mRNA (H) and miR143 (I) were examined by real RT-PCR and shown as means ± SEM (n = 3).
(J and K) Effects ofmiR-143 on HK2 expression. HK2 protein (J) and HK2mRNA levels (K) in PC3 cells transfectedwith control vector, miR-143 expression vector,
or miR-143 mimic were determined by western blot or RT-PCR.
(L) Schematic model addressing HK2 upregulation upon p53 deletion.
For western blots, tubulin was used as a loading control. *p% 0.01. ns, not statistically significant.HK2-depleted prostate cancer cells. Knockdown of HK2 in
UMN-4240P mouse Pten-/p53-deficient prostate cancer cells
decreased cell proliferation as indicated by the significant reduc-
tion of positive staining of cellular proliferation marker Ki67 (Fig-
ures 6G and 6H). Identical results were observed in xenograft
harboring human Pten-/p53-deficient prostate cancer PC3 cells
(Figures 6P and 6Q). However, HK2 depletion did not induce sig-
nificant apoptosis, since we found minimal changes in the pro-
portion of cells with cleaved caspase 3 (data not shown). These1468 Cell Reports 8, 1461–1474, September 11, 2014 ª2014 The Audata suggest that the impaired ability of HK2-depleted cells to
develop into tumors is primarily due to inhibition of cancer cell
proliferation. Taken together, the xenograft studies provide ge-
netic evidence that the Pten-/p53-deficient prostate cancer cells
require HK2-mediated glycolysis to fuel tumor growth in vivo.
HK2 Is Expressed in Human Prostate Cancer
Previous studies indicated that HK2 expression was observed
in several types of human tumor specimens, includingthors
Figure 6. Depletion of HK2 Suppresses Pten-/p53-Deficiency Driven Prostate Cancer Growth In Vivo
(A–C) Knockdown of HK2 inhibits glycolysis in mouse prostate cancer cells. UMN-4240P prostate cancer cell line was transduced with scramble shRNA (Con) or
shRNA targeting HK2 (shHK2). HK2 protein expression was detected by western blotting (A). Glucose consumption (B) and lactate production (C) from control or
HK2-depleted cells were analyzed.
(D) Cell proliferation upon HK2 depletion in UMN-4240P cells.
(E) Quantification of colonies generated by either control or HK2 knockdown UMN-4240P cells from three independent experiments.
(F–H) HK2 depletion in UMN-4240P cells on prostate tumorigenesis in vivo. Tumor growth curve in xenografts carrying control or HK2-depleted mouse prostate
cancer cells (F), IHC staining of cell proliferation marker Ki67 (G), and its quantification (H) from (G).
(legend continued on next page)
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glioblastoma multiforme (Wolf et al., 2011), lung, and breast
cancer samples (Patra et al., 2013). We did immunoblotting
to examine HK2 and HK1 expression in normal human prostate
tissues and cancer specimens. HK2 was exclusively expressed
in prostate cancers, whereas HK1 expression was observed
in both normal and cancerous tissues (Figure 7A). We then
analyzed tumor tissue microarray (TMA) of human prostate
cancer by IHC and observed that HK2 expression was signifi-
cantly elevated in prostate tumor samples compared with
normal prostate tissue, although the protein expression level
of HK2 was highly variable among individual tumors (Figures
7B–7D). Importantly, a significant correlation between HK2 pro-
tein expression and Gleason score was detected (Figures 7E
and 7F).
To explore whether the extent of HK2-specific alteration in
prostate cancer correlates with Pten and p53 loss/mutations,
we analyzed TMA for PTEN, p53, and HK2 expression by IHC
(Figure 7G). Since expression of wild-type p53 protein was
hardly detectable by IHC, negative staining of p53 could not be
distinguished from cancer cells carrying wild-type p53 or p53
deletions.We therefore focused on nuclear protein accumulation
of p53, a hallmark of the presence of p53 missense mutations
that contribute to more than 85% of p53 mutations identified in
human cancers (Muller and Vousden, 2014). Indeed, a high level
of HK2 expression was observed in eight out of nine tumor sam-
ples with negative staining of PTEN and positive staining of
mutant p53 (Figures 7G and S7), suggesting combined dele-
tion/mutation of Pten and p53 contributes to the elevated HK2
expression in human prostate cancer.
DISCUSSION
Recent studies suggest that tumor suppressor gene inactivation
alters glucose metabolism to favor the Warburg effect, which in
turn plays a causal role in tumorigenesis (Levine and Puzio-
Kuter, 2010). In our study, HK2 is almost exclusively expressed
in prostate cancer tissue in comparison with normal prostate tis-
sue (Figure 7A) and its protein expression level positively corre-
lates with Gleason score (Figures 7E and 7F). Although limited
by nine informative cases, a high level of HK2 expression has
been observed in eight prostate cancer samples with negative
staining of PTEN and positive staining of mutant p53 (Figures
7G and S8). Importantly, genetic studies demonstrate that the
HK2-mediated Warburg effect is required for the growth of
Pten-/p53-deficient prostate cancer cells in vitro and in xeno-
graft models carrying mouse or human Pten-/p53-deficient
prostate cancer cell lines in vivo (Figure 6). These results are
consistent with a previous study of glioblastoma that showed(I–K) HK2 depletion inhibits glycolysis in human prostate cancer cells. PC3 cells we
(shHK2-01 and shHK2-02). HK2 was detected by western blotting (I), and glucose
cells were analyzed.
(L) Colonies were stained by crystal violet after 10 days of cell growth.
(M and N) Cell growth in soft agar and colonies were photographed and counted a
survival clones (M), and the bar graph shows the average number of colonies (±S
(O–Q) Xenograft tumor growth assay in vivo. Average tumor weight (O), IHC stain
developed in NSG mice carrying control or HK2-depleted PC3 cells.
All data are shown as means ± SEM. For western blots, tubulin was used as a lo
1470 Cell Reports 8, 1461–1474, September 11, 2014 ª2014 The AuHK2 depletion by shRNAs inhibits tumor growth in a xenograft
model (Wolf et al., 2011). More recently, a study using HK2
conditional knockout mice showed that HK2 is required for
tumor initiation and maintenance in mouse models of Kras-
driven lung cancer and ErbB2-driven breast cancer (Patra
et al., 2013). Our study extended the biological significance of
HK2 to Pten-/p53-deficient prostate cancers, which are partic-
ularly relevant to the treatment of current incurable metastatic
CRPC for which taxane-based chemotherapeutics and/or
androgen- and/or androgen receptor-targeted molecular thera-
pies have limited efficacy. These findings therefore provide a
therapeutic strategy for CRPC through the targeting of its
heightened HK2-mediated glycolysis.
Although increased HK2 expression has been observed in
cancer cells and tumor tissues from mouse models or patients
(Patra et al., 2013; Wolf et al., 2011), our current study provides
significant insights into the underlying molecular mechanisms
for HK2 overexpression in cancer cells carrying Pten/p53
aberrations. Upon AKT activation, HK2 protein undergoes mito-
chondrial translocation (Majewski et al., 2004) through AKT-
mediated HK2 phosphorylation (Roberts et al., 2013). At the
transcriptional level, activation of the AKT-mTOR pathway
upregulates HK2 mRNA expression through induction of and
enhancement of hypoxia-inducible factors binding to the HK2
promoter (Mathupala et al., 2001). We here demonstrate that
activation of the AKT-mTORC1 signaling due to Pten deletion
increases HK2 expression primarily at the translational level
through phosphorylation of the 4EBP1 signaling. To recap the
key data, we have shown that loss of Pten in MEFs or in pros-
tate epithelium (Figures 3A and 3C) does not increase HK2
mRNA level yet enhances HK2 protein level (Figures 2G–2I).
Pten deletion in p53-deficient cells dramatically increases
HK2 protein expression (Figures 1C and 2) without further in-
duction of HK2 mRNA over that induced by p53 deletion alone
(Figures 3A and 3C), but instead with a significant enhancement
of polysome-associated HK2 mRNA (Figure 4B). Conversely,
shRNA-mediated inhibition of the AKT-mTORC1 signaling by
depletion of AKT or Raptor decreases HK2 protein expression
without reduction of HK2 mRNA level (Figure 3) through a signif-
icant reduction of polysome-associated HK2 mRNA (Figures 4C
and 4D). Active mTORC1 complex phosphorylates 4E-BP1,
which is therefore unable to bind to eIF4E. Thus, eIF4E is free
to bind to eIF4G, which forms the eIF4F complex on the 50
cap of mRNA and initiates translation (Laplante and Sabatini,
2012). In support of the critical role of phosphorylated 4EBP1
in regulation of HK2 mRNA translation, we showed that the
PI3K-mTOR dual inhibitor NVP-BEZ235, but not the allosteric
mTORC1 inhibitor rapamycin, significantly reduces HK2 proteinre transfectedwith scramble shRNA (Con) or two independent shRNAs for HK2
consumption (J) and lactate production (K) from control or HK2-depleted PC3
fter 21 days. Representative images of colonies are shown and arrows indicate
EM) of triplicates (N).
ing of cell proliferation marker Ki67 (P), and its quantification (Q) from tumors
ading control. *p% 0.01. Scale bar, 100 mm.
thors
(legend on next page)
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expression concordant with a marked inhibition of 4EBP1 phos-
phorylation (Figure 4E). More importantly, doxycycline-induced
expression of dominant-negative mutant of 4EBP1 (4EBP1M)
(Hsieh et al., 2010), which tightly binds to eIF4E due to reduc-
tion of phosphorylation, significantly suppresses HK2 protein,
but not HK2 mRNA (Figures 4F and S6F). These findings sup-
port that phosphorylated 4EBP1-mediated cap-dependent
translation is essential for the induction of HK2 protein in pros-
tate cancer cells harboring Pten deletion.
In reference to p53, an early study suggested that p53 in-
creases HK2 mRNA transcription through p53-responsive ele-
ments (Mathupala et al., 1997). In contrast, we observed that
loss of p53 enhances HK2mRNA expression in our experimental
settings (Figure 3).We have shown that exogenous expression of
wild-type p53 in p53-null prostate cancer cells reduces HK2
mRNA expression (Figure 5) and that genotoxic drug Adria-
mycin-induced endogenous p53 expression in p53-wild-type
cancer cells, but not in p53-deficient cancer cells, suppresses
HK2 mRNA, supporting p53 induction is required for the reduc-
tion of HK2 mRNA (Figure 5). Mechanistically, we demonstrated
that loss of p53 decreases the biogenesis of miR143, which
in turn leads to degradation of HK2 mRNA through binding
the 30 UTR. By overexpression of miR143 or administration of
miR143 mimics in p53-deficient prostate cancer cells, we
observed significant reduction of HK2 mRNA (Figure 5K), in sup-
port of miR143’s role as a direct effector to target HK2. These
results collectively indicate that the loss of p53 in prostate cancer
cells enhances HK2 protein expression by removal of miR143-
mediated degradation of HK2 mRNA.
In summary, our findings support that HK2 is coregulated by
the p53-miR143 axis at the mRNA/posttranscriptional level and
by PTEN-AKT-mTOR-4EBP1 signaling at the protein/transla-
tional level. As a result, the combined deficiency of Pten and
p53 in prostate cancer cells synergistically leads to robustly
elevated HK2 expression to fuel aggressive prostate cancer
growth in vivo.
EXPERIMENTAL PROCEDURES
Pten and/or p53 Mutant Mice
The conditional Ptenflox/flox mouse was generated as previously described
(Zheng et al., 2008). The conditional p53flox/flox mouse was generously
provided by Dr. A Berns (Jonkers et al., 2001). PB-Cre4 transgenic mice
were obtained from the NCI Mouse Repository. Female mice carrying
Ptenflox/+p53flox/+ were crossed with male mice harboring PB-Cre4+Ptenflox/+
p53flox/+ to generate mutant mice with prostate epithelium-specific deletion
of Pten and/or p53. Tail DNA was used for PCR-based genotyping. All animalFigure 7. HK2 Is Elevated in Human Prostate Cancers
(A) Lysates from human normal prostate and prostate tumor were immunoblotte
(B) IHC staining of HK2 expression in human normal prostate (n = 15) and prosta
(C) Quantification of HK2 staining intensity was analyzed with Image-Pro plus (v
(D) IHC staining of HK2 expression in human normal prostate and prostate tumo
normal tissue and tumors with identified Gleason score were shown.
(E) Quantification of HK2 staining intensity was analyzed with Image-Pro plus (v 6
follows: 15 normal, 7 Gleason 1–4, 33 Gleason 5–7, and 30 Gleason 8–10.
(F) Correlation between HK2 protein expression levels and Gleason score of hum
(G) Representative images of HK2 protein expression in human prostate cancer s
Normal prostate tissue served as a positive control for Pten (PtenP) and negative
See also Figure S7.
1472 Cell Reports 8, 1461–1474, September 11, 2014 ª2014 The Auprotocols were reviewed and approved by the University of Minnesota Institu-
tional Animal Care and Use Committee.
Generation of MEFs with Conditional Deletion of Pten and/or p53
MEFs were generated from 13.5-day embryos of a PtenFlox/+, p53Floxx/+, and
PtenFlox/+, p53Floxx/+ mating. To delete Pten and/or p53, primary MEFs with
floxed Pten alleles and/or floxed p53 alleles were transduced with a lentiviral
vector carrying Cre. Deletion of Pten and/or p53 was confirmed by both
PCR and western blot.
Generation of Prostate Cancer Cell Lines
The prostate tumors derived from mice carrying PB-Cre4+Ptenflox/flox
p53flox/flox were surgically removed and digested with collagenase solution
(STEMCELL Technologies) at 37C. Digested tumors were washed three times
with PBS to remove collagenase. The cell pellets were then suspended in
Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum,
and cells were grown at standard tissue culture condition. Stable polyclonal
tumor cell lines (UMN-4240P) were expanded for one to two generations
and frozen down for future experiments. Deletion of Pten and p53 in the pros-
tate cancer cell line was verified by both PCR and western blot.
Statistical Analyses
Statistical comparisons were analyzed by ANOVA (greater than two groups)
or Student’s t test (two groups only) with GraphPad Prism (v.5). Mann-Whitney
U test was used to assess differences of HK2 expression in human prostate
cancers. Spearman’s p was used to assess correlation. Statistical significance
was accepted at p < 0.05.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedure
and seven figures and can be found with this article online at http://dx.doi.
org/10.1016/j.celrep.2014.07.053.
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